AWM
CRSP icon

AE Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

AE Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$212K Buy
+3,891
New +$205K ﹤0.01% 1688
2024
Q1 		– Sell
-11,907
Closed -$726K – 1317
2023
Q4 		$726K Buy
11,907
+6,540
+122% +$362K ﹤0.01% 1275
2023
Q3 		$244K Sell
5,367
-1,784
-25% -$92.1K ﹤0.01% 1699
2023
Q2 		$401K Buy
7,151
+2,582
+57% +$147K ﹤0.01% 1493
2023
Q1 		$207K Buy
+4,569
New +$222K ﹤0.01% 1727
2022
Q4 		– Sell
-4,810
Closed -$314K – 1827
2022
Q3 		$314K Sell
4,810
-537
-10% -$38.9K ﹤0.01% 1460
2022
Q2 		$325K Buy
5,347
+1,205
+29% +$70.8K ﹤0.01% 1408
2022
Q1 		$260K Sell
4,142
-1,323
-24% -$83.1K ﹤0.01% 1487
2021
Q4 		$414K Sell
5,465
-1,444
-21% -$126K ﹤0.01% 1332
2021
Q3 		$773K Buy
6,909
+1,943
+39% +$244K 0.01% 963
2021
Q2 		$804K Buy
4,966
+76
+2% +$9.24K 0.01% 914
2021
Q1 		$596K Sell
4,890
-9,772
-67% -$1.48M 0.01% 949
2020
Q4 		$2.25M Buy
14,662
+3,442
+31% +$407K 0.03% 465
2020
Q3 		$938K Buy
+11,220
New +$995K 0.01% 656
2020
Q2 		– Sell
-5,015
Closed -$213K – 1272
2020
Q1 		$213K Buy
+5,015
New +$259K ﹤0.01% 988

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

AE Wealth Management's CRSP Position: Q2 2026 in Review

AE Wealth Management opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 3,891 shares worth $212K. The stake represents ﹤0.01% of the portfolio and ranks #1688 among its holdings. This is a return to the name: AE Wealth Management previously reported a position in CRSP as recently as Q4 2023.

AE Wealth Management first reported a position in CRSP in Q1 2020 and has held it in 15 quarters since. The position peaked at $2.25M in Q4 2020. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • AE Wealth Management held 3,891 shares of CRISPR Therapeutics worth $212K as of Q2 2026.
  • CRISPR Therapeutics was a new AE Wealth Management position in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of AE Wealth Management's portfolio in Q2 2026, its #1688 holding.
  • AE Wealth Management first reported a position in CRISPR Therapeutics in Q1 2020 and has held it in 15 quarters since.
  • AE Wealth Management's CRISPR Therapeutics position peaked at $2.25M in Q4 2020.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on AE Wealth Management's 13F filing for Q2 2026, filed 3 Aug 2026.